Developing Rapid-Acting Treatments for Neuropsychiatric Diseases

See latest data
Our Focus

TSND-201
a rapid-acting neuroplastogen
for PTSD

We are excited to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. 
Learn More
News

The Latest From Transcend

Transcend Therapeutics Presents New Data from the Open-Label Portion of the IMPACT-1 Study and Further Data Supporting the Neuroplasticity Mechanism of TSND-201 Read More
Press Release

Transcend Therapeutics Presents New Data from the Open-Label Portion of the IMPACT-1 Study and Further Data Supporting the Neuroplasticity Mechanism of TSND-201
TSND-201 (Methylone) for the Treatment of PTSD: Improvements across each CAPS-5 Cluster and Anxiety Symptoms from the Open-Label Portion of the IMPACT-1 Study Read More
Poster Presentation

TSND-201 (Methylone) for the Treatment of PTSD: Improvements across each CAPS-5 Cluster and Anxiety Symptoms from the Open-Label Portion of the IMPACT-1 Study
TSND-201 (Methylone): A Rapid-Acting Neuroplastogen that Stimulates Neurite Outgrowth Read More
Poster Presentation

TSND-201 (Methylone): A Rapid-Acting Neuroplastogen that Stimulates Neurite Outgrowth
Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone) Read More
Press Release

Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone)
Learn More
Our Mission

Striving for a world without neuropsychiatric disease.

Because 1 billion patients
deserve better.
Careers

Help us bring new mental health solutions to patients

Join us in creating a world free from neuropsychiatric disease.
Learn More